• Seres Therapeutics released early top-line data from an MSK investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis.
• At Day 15, 12 of 15 patients (80%) met the primary endpoint: immunosuppressive-free clinical response in diarrhea; 5 of 15 (33%) reached remission.
• At Day 43, 5 of 15 (33%) maintained response; SER-155 was generally well tolerated with no drug-related serious adverse events.
• Seres scheduled a webcast today at 8:30 a.m. ET; details at https://www.serestherapeutics.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.